Bupropion as a modulator of drug activity
View Patent ↗Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
1. A method of inhibiting metabolism of dextromethorphan in a human being comprising co-administering: 1) an oral dosage form containing bupropion, with 2) about 35 mg per day to about 500 mg per day of dextromethorphan to the human being once or twice a day for at least eight consecutive days, wherein the human being is an extensive metabolizer of dextromethorphan in need of treatment with dextromethorphan, and wherein on the eighth day that bupropion and dextromethorphan are co-administered, the co-administration results in an AUC 0-12 of dextromethorphan that is at least about 20 times the AUC 0-12 that would be achieved by administering the same amount of dextromethorphan without bupropion for eight consecutive days.
2. The method of claim 1 , wherein the AUC 0-12 of dextromethorphan, on the eighth day that bupropion and dextromethorphan are co-administered, is at least about 500 ng·hr/mL.
3. The method of claim 1 , wherein the AUC 0-inf of dextromethorphan, on the eighth day that bupropion and dextromethorphan are co-administered, is at least about 1000 ng·hr/mL.
4. The method of claim 1 , wherein the AUC 0-inf of dextromethorphan, on the eighth day that bupropion and dextromethorphan are co-administered is at least about 2000 ng·hr/mL.
5. The method of claim 1 , wherein the C max of dextromethorphan, on the eighth day that bupropion and dextromethorphan are co-administered, is at least about 10 ng/mL.
6. The method of claim 1 , wherein the C max of dextromethorphan, on the eighth day that bupropion and dextromethorphan are co-administered, is at least about 40 ng/mL.
7. The method of claim 1 , wherein the C max of dextromethorphan, on the eighth day that bupropion and dextromethorphan are co-administered, is at least about 60 ng/mL.
8. The method of claim 1 , wherein an excess of one stereoisomer of bupropion is administered.
9. The method of claim 1 , wherein an excess of the S-enantiomer of bupropion is administered.
10. The method of claim 1 , wherein an excess of the R-enantiomer of bupropion is administered.
11. The method of claim 1 , wherein the bupropion is administered in an oral dosage form that is sustained-release for bupropion.
12. The method of claim 1 , wherein the dextromethorphan is administered in an oral dosage form that is immediate-release for dextromethorphan.
13. The method of claim 11 , wherein the dextromethorphan is administered in an oral dosage form that is immediate-release for dextromethorphan.
14. The method of claim 1 , wherein about 60 mg to about 140 mg of dextromethorphan is administered to the human being per day.
15. The method of claim 1 , further comprising co-administering the oral dosage form containing bupropion with about 35 mg per day to about 500 mg per day of dextromethorphan to the human being for at least fourteen consecutive days.
16. The method of claim 1 , further comprising co-administering the oral dosage form containing bupropion with about 35 mg per day to about 300 mg per day of dextromethorphan to the human being for at least 30 consecutive days.
17. The method of claim 1 , wherein the bupropion is administered in a sustained-release manner and the dextromethorphan is administered in an immediate-release manner.
18. A method of increasing exposure to dextromethorphan in a human being comprising co-administering: 1) a dosage form containing bupropion, with 2) about 40 mg per day to about 500 mg per day of dextromethorphan to the human being for at least fourteen consecutive days, wherein the human being is an extensive metabolizer of dextromethorphan in need of treatment with dextromethorphan, wherein bupropion and dextromethorphan are co-administered once or twice a day, and wherein on the eighth day that bupropion and dextromethorphan are co-administered, the co-administration results in an AUC 0-12 of dextromethorphan that is at least about 15 times the AUC 0-12 that would be achieved by administering the same amount of dextromethorphan without bupropion for eight consecutive days.
19. The method of claim 18 , wherein the bupropion and the dextromethorphan are administered in a single dosage form.
20. The method of claim 18 , wherein the bupropion is administered in a dosage form that is sustained-release for bupropion.
21. The method of claim 18 , wherein the bupropion is administered in a sustained-release manner and the dextromethorphan is administered in an immediate-release manner.
22. The method of claim 19 , wherein the single dosage form is sustained-release for bupropion and immediate-release for dextromethorphan.
23. The method of claim 18 , wherein the AUC 0-12 of dextromethorphan, on the eighth day that bupropion and dextromethorphan are co-administered, is at least about 500 ng·hr/mL.
24. The method of claim 18 , wherein the C max of dextromethorphan on the eighth day that bupropion and dextromethorphan are co-administered, is at least about 10 ng/mL.
25. The method of claim 18 , wherein the C avg of dextromethorphan on the eighth day that bupropion and dextromethorphan are co-administered, is at least about 100 ng/mL.
26. The method of claim 18 , wherein an excess of one stereoisomer of bupropion is administered.
27. The method of claim 18 , wherein an excess of the S-enantiomer of bupropion is administered.
28. The method of claim 18 , wherein an excess of the R-enantiomer of bupropion is administered.
29. The method of claim 18 , wherein about 60 mg to about 120 mg of dextromethorphan is administered to the human being per day.
30. The method of claim 18 , further comprising co-administering the dosage form containing bupropion with about 60 mg per day to about 200 mg per day of dextromethorphan to the human being for at least 30 consecutive days.